Skip to content

An explorative intervention study to investigate the feasibility and safety of oral immunotherapy with different allergens in young children diagnosed with food allergy.

An explorative intervention study to investigate the feasibility and safety of oral immunotherapy with different allergens in young children diagnosed with food allergy. - Oral immunotherapy in young children diagnosed with food allergy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON49735
Enrollment
183
Registered
2019-01-21
Start date
2019-05-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food allergy

Interventions

Children who are enrolled in the ORKA study start with the OIT (daily intake of a small amount of food for which the patient is allergic) within about 2 weeks after the provocation test. After the m

Sponsors

Deventer Ziekenhuis
Lead Sponsor

Eligibility

Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: • Children with an age of 9 to 24 months. • A proven food allergy (positive provocation and sensitization demonstrated by a skin prick test> 3mm and / or sIgE> 0.35kU / L) for chicken egg, peanut, cow's milk, cashewnut, hazelnut, walnut and/or one of the more rare allergens (as soja, pits and seeds (sesameseed and pine nut) and wheat). • Assessment of the presence of other food allergies (standard care) by introduction in the diet and / or the determination of sensitization. From the mentioned allergens, introduction into the diet or the diagnosis food allergy has been made. • Written permission (signed informed consent form) from both parents / guardian for participation in the study.

Exclusion criteria

Exclusion criteria: • Uncontrolled toddler asthma and / or frequent exacerbations (viral wheezing) defined as toddlers who have been admitted to hospital > 1x in the past six months because of these complaints. • Uncontrolled eczema. • Severe gastrointestinal complaints such as gastroesophageal reflux disease, where an underlying disease such as eosinophilic esophagitis (EoE) cannot be excluded. • Active EoE. • Mastocytosis (also cutaneous). • Psycho-social problems in the family that may be a barrier to a good daily performance of long-term therapy. • Inability of parents to follow instructions, to recognize allergic reactions or to administer emergency medication. • Participation in any other intervention study at the time of the ORKA study, with the exception of studies on guided early introduction of high-allergenic nutrition.

Design outcomes

Primary

MeasureTime frame
Safety based on the number of anaphylactic reactions that occur within 2 hours after administration of the food product. Feasibility as assessed by both parents and doctors. Effectiveness measured as the number of children with long-term tolerance (SU): a negative provocation test 4 weeks after the discontinuation of the OIT and a problem-free introduction of the food allergen in the diet, and the number of children with remission: a negative food provocation at least 2 years after cessation of OIT, with strict avoidance of the specific food allergen in in the 12 weeks preceding the provocation test.

Secondary

MeasureTime frame
• Number of children with sustained unresponsiveness: a negative food challenge 4 weeks after discontinuation of OIT. • Number of children with a problem-free introduction of the food allergen in the diet 6 months after discontinuation of the OIT. • Number of children with food allergy remission: a negative food provocation at least 2 years after cessation of OIT, with strict avoidance of the specific food allergen in the 12 weeks preceding the food provocation

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)